V BWA WCC AMP AMZN MCK MCK WHR FDX FDX WHR INTU COF ROC URI AET AIZ FRX LTD LNC GRA ABC STT STT UTHR VLO LLTC ALKS TCS WNR DGI CAR MDLZ GOGO TSN CSX MU ASNA GPC STZ VRSN WYN STJ ABBV ADSK CF WDC HPQ
Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with integrated commercial and drug development operations with a focus in hematology and oncology. In the United States, it markets two oncology drugs, ZEVALIN and FUSILEV and have two drugs, apaziquone and belinostat, in late stage development along with a pipeline of drug candidates. Apaziquone is studied in two phase-III clinical trials for non-muscle invasive bladder cancer (NMIBC), under strategic collaborations with Allergan, Inc. (Allergan), Nippon Kayaku Co. Ltd. (Nippon Kayaku), and Handok Pharmaceuticals Co. Ltd. (Handok). Belinostat is being studied in multiple indications, including a phase-II registrational trial for relapsed or refractory peripheral T-cell lymphoma (PTCL), under a strategic collaboration with TopoTarget A/S (TopoTarget). On September 5, 2012, it acquired Allos Therapeutics, Inc.